Compare FEMY & ORIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FEMY | ORIS |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Farming/Seeds/Milling |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.4M | 41.2M |
| IPO Year | 2021 | 2024 |
| Metric | FEMY | ORIS |
|---|---|---|
| Price | $0.65 | $1.55 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $6.83 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 629.5K |
| Earning Date | 11-14-2025 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | $2,061,502.00 | ★ $12,317,000.00 |
| Revenue This Year | $64.02 | N/A |
| Revenue Next Year | $147.19 | N/A |
| P/E Ratio | ★ N/A | $198.58 |
| Revenue Growth | ★ 63.53 | N/A |
| 52 Week Low | $0.31 | $1.11 |
| 52 Week High | $1.80 | $45.60 |
| Indicator | FEMY | ORIS |
|---|---|---|
| Relative Strength Index (RSI) | 45.02 | 66.52 |
| Support Level | $0.60 | $1.34 |
| Resistance Level | $0.73 | $1.87 |
| Average True Range (ATR) | 0.06 | 0.18 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 45.12 | 54.61 |
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
Oriental Rise Holdings Ltd is an integrated supplier of tea products in China. It is principally engaged in the business of planting, cultivating, processing, and selling processed tea. The company currently produces and sells three categories of products: roughly processed white tea, roughly processed black tea, and refined tea. The company's business operations are vertically integrated, covering cultivation, processing of tea leaves, and the sale of tea products to tea business operators and end-user retail customers. Geographically, the company generates all of its revenue from its business in the People's Republic of China (the PRC).